Compare Davita Inc (DVA) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Davita Inc trades at $179.09 (market cap $11.29B), while Rex Fang & Innovation Equity Premium Income ETF trades at $43.54 (market cap $746.48M). The key difference: Davita Inc is far larger — about 15.1× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Davita Inc is more actively traded (582,204 versus 334,337). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Rex Fang & Innovation Equity Premium Income ETF for 56 Days on average.
| DVA | FEPI | |
|---|---|---|
Market Cap | $11.29B | $746.48M |
Volume | 582,204 | 334,337 |
Sector | Health | Income / Options Overlay |
52-Week High | $240.96 | $49.54 |
52-Week Low | $103.87 | $37.98 |
Typical Hold Time | 114 Days | 56 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
FEPI (REX FANG & Innovation Equity Premium Income ETF) trades at $43.59, down 0.17% on the day, with a bullish technical signal supported by moving averages. The ETF employs a covered call strategy on AI and tech mega-caps, generating weekly dividends averaging $0.20-0.21 per share. Recent news highlights its high yield but notes underperformance versus peers in total return.
Outlook: High income potential via dividends but capped upside from call-writing. Risks include concentrated tech exposure, volatility sensitivity, and competitive pressure from alternative yield strategies. Neutral sentiment prevails amid yield appeal and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
